AI-Designed Drugs by a DeepMind Spinoff Are Headed to Human Trials

Isomorphic Labs, an innovative biotech company spun out from Google DeepMind, is on the verge of bringing its AI-created drugs into human clinical trials. President Max Jaderberg announced at WIRED Health in London that their drug pipeline, driven by advanced artificial intelligence, represents a significant leap forward in medicine development.

Revolutionizing Drug Discovery with AI

Central to Isomorphic Labs’ approach is AlphaFold, DeepMind’s cutting-edge AI system that accurately predicts protein structures—a major milestone achieved in 2020 and expanded in subsequent years. Building on this technology, Isomorphic Labs launched AlphaFold 3, which enables the modeling of not only proteins, but also DNA, RNA, and their interactions. This holistic understanding is essential for designing more precise and effective drugs.

From Research to Clinical Impact

The company’s latest tool, IsoDDE, reportedly doubles the accuracy of AlphaFold 3, further refining its drug design capabilities. These advances have positioned Isomorphic Labs as a leader in the industry, securing partnerships with pharmaceutical giants like Eli Lilly and Novartis, and expanding their own research pipelines in cancer and immune diseases.

Aiming High: New Medicines and Ambitions

According to Jaderberg, AI-powered drug design allows for the creation of molecules that are highly potent and require lower doses, resulting in fewer side effects. The company’s recent $600 million funding round and leadership appointments signal a strong commitment to turning this vision into reality.

The Road Ahead

Isomorphic Labs is preparing for its first clinical trials, marking a crucial test for its AI-designed molecules. The ultimate goal? To address and potentially “solve all disease,” a mission that the company approaches with serious intent and robust scientific innovation.

For more details, read the original article on WIRED.